Adaptive Enterprise Value vs Invested Capital Analysis
ADPT Stock | USD 2.89 0.01 0.35% |
Trend analysis of Adaptive Biotechnologies Corp balance sheet accounts such as Other Current Liab of 19.9 M, Total Current Liabilities of 84.7 M or Total Stockholder Equity of 347 M provides information on Adaptive Biotechnologies' total assets, liabilities, and equity, which is the actual value of Adaptive Biotechnologies to its prevalent stockholders. By breaking down trends over time using Adaptive Biotechnologies balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Adaptive |
About Adaptive Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Adaptive Biotechnologies at a specified time, usually calculated after every quarter, six months, or one year. Adaptive Biotechnologies Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Adaptive Biotechnologies and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Adaptive currently owns. An asset can also be divided into two categories, current and non-current.
Adaptive Biotechnologies Balance Sheet Chart
Adaptive Biotechnologies Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Adaptive Biotechnologies uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Adaptive Biotechnologies' Short Term Investments are comparatively stable compared to the past year. Long Term Debt Total is likely to gain to about 44.2 M in 2024, whereas Other Liabilities is likely to drop slightly above 125.4 M in 2024. Add Fundamental
Total Assets
Total assets refers to the total amount of Adaptive Biotechnologies assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Adaptive Biotechnologies books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Adaptive Biotechnologies balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Adaptive Biotechnologies Corp are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Adaptive Biotechnologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adaptive Biotechnologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. Selling General Administrative is likely to drop to about 57.1 M in 2024. Enterprise Value Multiple is likely to drop to -5.1 in 2024
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 105.0M | 127.4M | 72.5M | 78.9M | Total Revenue | 154.3M | 185.3M | 170.3M | 123.7M |
Adaptive Biotechnologies fundamental ratios Correlations
Click cells to compare fundamentals
Adaptive Biotechnologies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Adaptive Biotechnologies fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 912.3M | 1.1B | 923.3M | 856.6M | 661.1M | 811.6M | |
Other Current Liab | 12.9M | 25.1M | 25.0M | 28.4M | 22.3M | 19.9M | |
Total Current Liabilities | 78.3M | 105.2M | 113.8M | 109.8M | 88.0M | 84.7M | |
Total Stockholder Equity | 571.0M | 743.3M | 604.0M | 464.2M | 308.4M | 347.0M | |
Other Liab | 226.3M | 163.6M | 98.8M | 184.0M | 211.6M | 125.4M | |
Net Tangible Assets | 440.1M | 614.1M | 476.5M | 338.4M | 389.1M | 205.2M | |
Property Plant And Equipment Net | 60.4M | 139.0M | 172.9M | 164.2M | 120.3M | 108.4M | |
Current Deferred Revenue | 61.0M | 73.3M | 80.5M | 64.1M | 48.6M | 55.7M | |
Net Debt | (60.0M) | (15.6M) | (27.3M) | 18.0M | 164.4M | 172.6M | |
Retained Earnings | (365.5M) | (511.6M) | (718.9M) | (919.1M) | (1.1B) | (1.1B) | |
Accounts Payable | 4.5M | 3.2M | 3.3M | 8.1M | 7.7M | 4.8M | |
Cash | 96.6M | 123.4M | 139.1M | 90.0M | 65.1M | 102.9M | |
Non Current Assets Total | 299.6M | 389.5M | 520.6M | 294.5M | 250.9M | 324.4M | |
Non Currrent Assets Other | 2.9M | 2.7M | 3.0M | 4.5M | (1.5M) | (1.5M) | |
Other Assets | 39.5M | 2.7M | 3.0M | 4.5M | 4.0M | 6.7M | |
Cash And Short Term Investments | 576.9M | 688.3M | 353.1M | 498.2M | 346.4M | 443.1M | |
Net Receivables | 12.7M | 10.0M | 17.4M | 40.1M | 39.0M | 20.4M | |
Common Stock Shares Outstanding | 69.2M | 131.2M | 140.4M | 142.5M | 144.4M | 131.8M | |
Short Term Investments | 480.3M | 564.8M | 214.0M | 408.2M | 281.3M | 340.3M | |
Liabilities And Stockholders Equity | 912.3M | 1.1B | 923.3M | 856.6M | 661.1M | 811.6M | |
Non Current Liabilities Total | 263.0M | 268.0M | 205.4M | 282.7M | 264.8M | 276.3M | |
Capital Surpluse | 935.8M | 1.3B | 1.3B | 1.4B | 1.6B | 910.1M | |
Inventory | 9.1M | 14.1M | 19.3M | 14.5M | 14.4M | 13.2M | |
Other Current Assets | 14.1M | 14.5M | 13.0M | 9.4M | 10.4M | 10.6M | |
Other Stockholder Equity | 23.5M | 1.3B | 1.3B | 1.4B | 1.5B | 865.0M | |
Total Liab | 341.3M | 373.1M | 319.2M | 392.5M | 352.9M | 337.9M | |
Net Invested Capital | 571.0M | 743.3M | 604.0M | 464.2M | 308.4M | 347.0M | |
Property Plant And Equipment Gross | 60.4M | 139.0M | 172.9M | 164.2M | 193.6M | 119.9M | |
Total Current Assets | 612.7M | 726.9M | 402.7M | 562.1M | 410.2M | 487.2M | |
Accumulated Other Comprehensive Income | 671K | 893K | (1.1M) | (4.1M) | 215K | 225.8K | |
Net Working Capital | 534.4M | 621.7M | 288.9M | 452.4M | 322.2M | 402.6M | |
Intangible Assets | 11.9M | 10.2M | 8.5M | 6.8M | 5.1M | 8.2M |
Pair Trading with Adaptive Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptive Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptive Stock
0.72 | MBRX | Moleculin Biotech Upward Rally | PairCorr |
0.87 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
Moving against Adaptive Stock
0.86 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
0.74 | MDWD | Mediwound Financial Report 4th of June 2024 | PairCorr |
0.66 | MGNX | MacroGenics Financial Report 14th of May 2024 | PairCorr |
0.64 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Adaptive Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptive Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptive Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptive Biotechnologies Corp to buy it.
The correlation of Adaptive Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptive Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptive Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptive Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Adaptive Stock analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Transaction History View history of all your transactions and understand their impact on performance | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
CEOs Directory Screen CEOs from public companies around the world | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.56) | Revenue Per Share 1.179 | Quarterly Revenue Growth (0.17) | Return On Assets (0.17) | Return On Equity (0.58) |
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.